Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294331 | 1.00 | PDE10A (0.47) | PDE10ADRD3SLC6A3DRD2CHRNA7 | |
| SCHEMBL2298028 | 1.00 | PDE10A (0.47) | PDE10ADRD3SLC6A3DRD2CHRNA7 | |
| SCHEMBL10747371 | 0.84 | PDE10A (0.46) | PDE10ADRD3SLC6A3DRD2 | |
| SCHEMBL12919984 | 0.83 | HPGD (0.44) | PDE10ADRD3SLC6A3 | |
| SCHEMBL24394471 | 0.83 | PDE10A (0.47) | PDE10ADRD3 | |
| SCHEMBL2293905 | 0.83 | PDE10A (0.47) | PDE10ADRD3 | |
| SCHEMBL2299971 | 0.83 | PDE10A (0.47) | PDE10ADRD3 | |
| SCHEMBL2298311 | 0.83 | DRD3 (0.41) | DRD3SLC6A3DRD2 | |
| SCHEMBL2294863 | 0.83 | DRD3 (0.41) | DRD3SLC6A3DRD2 | |
| SCHEMBL14862784 | 0.83 | DRD3 (0.41) | DRD3SLC6A3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877745-B2 | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | CCR2, CXCR2, CYSLTR2 | PDE10A 1829/4885DRD3 1107/4885SLC6A3 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.